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Abstract
To analyze the effect of bombesin on the somatostatin (SS) mechanism of action in the exocrine pancreas, male Wistar rats (250–270
g) were injected intraperitoneally with bombesin (10mg/kg) three times daily at 8-h intervals for 7 or 14 days. Bombesin attenuated the
ability of SS to inhibit forskolin-stimulated adenylyl cyclase activity in pancreatic acinar membranes. However, it did not decrease the ability
of forskolin to stimulate the adenylyl cyclase catalytic subunit. The ability of 59-guanylylimidodiphosphate [Gpp(NH)p] (a nonhydrolyzable
GTP analog) to inhibit forskolin-stimulated adenylyl cyclase activity was diminished in pancreatic acinar cell membranes from bombesin-
treated rats. Bombesin administration did not affect the ADP-ribosylation of a 41-kDa G protein catalyzed by pertussis toxin. The maximal
SS binding capacity of pancreatic acinar membranes from bombesin-treated rats was decreased when compared with controls at the two time
periods studied. The bombesin/gastrin-releasing peptide antagonist [D-Tpi6,Leu13c(CH2NH)Leu
14]bombesin (6–14) (RC-3095) (10mg/kg
ip), injected three times daily at 8-h intervals for 7 or 14 days, had a similar effect to that of bombesin on the SS mechanism of action. The
combined administration of bombesin and its antagonist RC-3095 had a greater effect on the SS receptor–effector system than when
administered separately. The present study indicates that the pancreatic SS receptor–effector system may be regulated by bombesin in vivo.
© 1999 Elsevier Science Inc. All rights reserved.
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1. Introduction
Bombesin, a tetradecapeptide originally isolated from
amphibian skin [2], belongs to a family of structurally
related peptides recently characterized in amphibians as
well as in mammals [52]. It is a neural peptide present in
enteric and intrapancreatic nerves [18,35]. Bombesin is
known to play a role as a neurotransmitter in the exocrine
pancreas [19,25]. Receptors for bombesin and related pep-
tides have been functionally and structurally identified in
several cell systems [24,50], including the exocrine pan-
creas [24]. A great deal of interest has been generated by the
demonstration that bombesin-like peptides are potent mito-
gens in different cell types [8,41,52], including pancreatic
acinar cells [29,31]. In the latter tissue, bombesin has long
been known to be a powerful stimulant of secretion [11] and
of electrical activity [23]. Thus, the effects of exogenously
administered bombesin in vivo could be the result of a direct
action on the pancreas. This does not discard the possibility
that the effects of bombesin on the exocrine pancreas are
also mediated through the modulation of other hormones
that act on the pancreatic acinar cells. In this regard it has
recently been shown that pretreatment of pancreatic acini
with bombesin reduces subsequent binding of labeled so-
matostatin (SS) to acinar membranes [44]. The tetrade-
capeptide SS has been shown to exert a negative control on
bombesin receptor-stimulated phosphatidylinositol turnover
[32]. In addition, SS and bombesin have contrary effects on
exocrine pancreatic secretion [3,21]. However, to date, the
effect of bombesin on the postreceptor SS mechanism of
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action is unknown. In pancreatic acinar cells, SS receptors
[12,42,46] are coupled to the adenylate cyclase (AC) en-
zyme system via the guanine nucleotide binding inhibitory
protein Gi [43]. The extent of Gi modification correlates
with the ability of SS to inhibit adenosine 39,59-cyclic
monophosphate (cAMP) formation.
In the present study, we investigated the effects of bomb-
esin and a new short chain pseudononapeptide bombesin/
gastrin-releasing peptide (GRP) antagonist, [D-Tpi6,Leu13c(CH2
NH)Leu14]bombesin (6–14) (RC-3095), on SS inhibition of
forskolin (FK)-stimulated AC activity, the overall catalytic
activity of AC by means of stimulation of the AC catalytic
subunit with FK, specific [125I-Tyr11]somatostatin ([125I-
Tyr11]SS) binding and its inhibition by the stable GTP
analog 59-guanylylimidodiphosphate [Gpp(NH)p] [43] and
pertussis toxin (PTX)-sensitive inhibitory GTP binding pro-
teins (Gi proteins) in rat pancreatic acinar membranes. In
addition, the effects of these compounds on pancreatic so-
matostatin-like-immunoreactive content (SSLI) was exam-
ined. Because bombesin increases cholecystokinin (CCK)
and gastrin release, it is possible that these hormones may
mediate the effects of bombesin on the SS receptor-effector
system. The pretreatment with proglumide (PG), a gastrin/
CCK receptor antagonist [39], was used to evaluate whether
the effects of bombesin on the pancreatic somatostatinergic
system involved the activation of gastrin/CCK receptors.
We present evidence that the ability of Gpp(NH)p to
inhibit FK-stimulated AC activity is diminished in pancre-
atic acinar cell membranes from bombesin-treated rats in
addition to an already reported decrease in SS receptor
levels in rat pancreatic acinar membranes. Likewise, evi-
dence that bombesin and its antagonist RC-3095 have sim-
ilar effects on the SS receptor–effector system in rat pan-
creatic acinar membranes is also introduced.
2. Methods
2.1. Experimental animals
Male Wistar rats (250–270 g) were injected intraperito-
neally three times daily at 8-h intervals during 7 or 14 days
[9,50] with the following agents: bombesin alone (10mg/
kg), PG alone (20 mg/kg), RC-3095 alone (10mg/kg),
bombesin combined with PG, and bombesin combined with
RC-3095 and saline in a volume (250:l) equal to that of the
other compounds. Drug doses were selected according to
the effective doses reported in previous studies [10,30]. Rats
were decapitated 18 to 20 h after the last injection. The
pancreas was removed and trimmed free of fat, connective
tissue, and lymph nodes.
2.2. Chemicals
Synthetic Tyr11-SS was purchased from Universal Bio-
logicals Ltd (Cambridge, UK); carrier-free125I-Na (IMS
300, 100 mCi/ml) was obtained from the Radiochemical
Center (Amersham, UK); bombesin, PG, FK, bacitracin,
phenylmethylsulfonyl fluoride, guanosine triphosphate
(GTP), Gpp(NH)p; 3-isobutyl-1-methylxanthine, PTX, and
bovine serum albumin (BSA) were purchased from Sigma
(St Louis, MO, USA). Bombesin receptor antagonist [D-Tpi6,
Leu13c(CH2NH)Leu
14]bombesin (6–14) or RC-3095, origi-
nally synthesized by Radulovic et al. [40] and Cai et al. [6],
was provided by Asta Pharma (Frankfurt/M, Germany). Tpi
[2,3,4,9,-tetrahydro-1H-pyrido(3,4-b)indol-3-carboxylic acid]
is a conformationally constrained analog of Trp and is more
hydrophobic than Trp. The rabbit antibody used in the radio-
immunoassay technique was purchased from the Radiochem-
ical Center (Amersham, UK). This antiserum was raised in
rabbits against SS-14 conjugated to BSA and is specific for
SS-14. Because SS-14 constitutes the C-terminal portions of
both SS-25 and SS-28, the antiserum does not distinguish
between these three forms. All other reagents were of the
highest purity commercially available.
2.3. Preparation of rat pancreatic acinar membranes
Dispersed pancreatic acini were obtained from male
Wistar rats after enzymatic degradation of the organ with
0.2 U of collagenase/ml in an oxygenated Krebs–Ringer
medium as described by Amsterdam et al. [1]. After thor-
ough washing by sedimentation, acini were homogenized in
0.3 M sucrose at 4°C by use of a Potter homogenizer fol-
lowing the method of Meldolesi et al. [34]. After sedimen-
tation at 1500g for 12 min, the homogenized membranes
were resuspended in 1.56 M sucrose. This suspension was
overlaid with 0.3 M sucrose and centrifuged at 105 000g
for 150 min. The plasma membrane-enriched fraction col-
lected from the interphase was diluted with distilled water
and centrifuged at 15 000g for 30 min. The supernant was
discarded and the pellet was resuspended in 50 mM Tris-
HCl, pH 7.4, 0.01 mg/ml bacitracin, and 0.2 mM CaCl2 and
stored at270°C. An aliquot was taken for protein determi-
nation by the method of Lowry et al. [33].
2.4. Binding of [125I-Tyr11]SS
Binding of [125I-Tyr11]SS was performed on rat pancre-
atic acinar membranes by a modification of the method of
Colás et al. [7]. Tyr11-SS was radioiodinated by the chlo-
ramine-T method as described by Greenwood et al. [15].
Separation of iodinated SS from free iodine was performed
on a Sephadex G-25 (fine) column using 0.1 M acetic acid
with BSA (0.1%, wt/vol). The specific activity of the radio-
ligand was 600 Ci/mmol. Binding of [125I-Tyr11]SS to pan-
creatic acinar membranes was performed in a total volume
of 250ml in 50 mM Tris-HCl buffer (pH 7.4) containing 0.5
mM MgCl2, 3 mM NaCl, 0.2 mM CaCl2, 0.2% (wt/vol)
BSA, 0.5 mg/ml bacitracin, and 0.3 mg/ml soybean trypsin
inhibitor (binding buffer). Plasma membranes (75mg of
protein/ml) were incubated for 90 min at 20°C with 35 pM
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[125I-Tyr11]SS in the absence or presence of 0.01 to 10 nM
unlabeled SS. Bound and free ligand were separated by
centrifugation at 11 000g for 4 min at 4°C in a microcen-
trifuge. Radioactivity in the pellet was measured with a
gamma counter. Nonspecific binding was estimated as
membrane-associated radioactivity in the presence of 1mM
SS and specific binding was calculated as the difference
between total and nonspecific membrane-associated radio-
activity. The effects of Gpp(NH)p on [125I-Tyr11]SS binding
were determined after addition of various Gpp(NH)p con-
centrations (10211–1024 M) to the binding assay buffer.
2.5. Evaluation of radiolabeled peptide degradation
To determine the extent of tracer degradation during
incubation, we measured the ability of preincubated peptide
to bind to fresh pancreatic acinar membranes after an initial
preincubation of the peptide. In brief, [125I-Tyr11]SS (35
pM) was incubated with pancreatic acinar membranes (75
mg of protein/ml) for 90 min at 20°C. After this preincuba-
tion, aliquots of the medium were added to fresh pancreatic
acinar membranes and incubated for an additional 90 min at
20°C. The fraction of the added radiolabeled peptide that
was specifically bound during the second incubation was
measured and expressed as a percentage of the binding
obtained in control experiments performed in the absence of
pancreatic acinar membranes during the preincubation pe-
riod.
2.6. Adenylyl cyclase assay
AC activity was measured as previously reported by
Houslay [20] with minor modifications. In brief, rat pancre-
atic acinar membranes (0.12 mg of protein/ml) were incu-
bated with 1.5 mM ATP, 5 mM MgSO4, 1 mM GTP and an
ATP-regenerating system (7.5 mg/ml creatine phosphate
and 1 mg/ml creatine kinase), 1 mM 3-isobutyl-1-methyl-
xanthine, 0.1 mM phenylmethylsulfonyl fluoride, 1 mg/ml
bacitracin, 1 mM EDTA, and tested substances (1029 M
SS-14 or 1025 M FK) in 0.1 ml of 0.025 M triethanolamine/
HCl buffer (pH 7.4). After a 30-min incubation at 30°C, the
reaction was stopped by heating the mixture for 3 min. After
cooling, 0.2 ml of an alumina slurry (0.75 g/ml in trietha-
nolamine/HCl buffer, pH 7.4) was added and the suspension
was centrifuged. The supernatant was taken for assay of
adenosine 39,59-cyclic monophosphate (cAMP) by the Gil-
man method [14].
2.7. Tissue extraction and SS radioimmunoassay
For measurement of somatostatin-like-immunoreactive
content, the pancreata were rapidly homogenized in 1 ml of
2 M acetic acid, using a Brinkman Polytron (setting 5, 30 s).
The extracts were boiled for 5 minutes and aliquots (100ml)
were removed for protein determination as described by
Lowry et al. [33]. The homogenates were subsequently
centrifuged at 15 000g for 15 min at 4°C and the superna-
tant was neutralized with 2 M NaOH. The extracts were
stored at270°C until assay. The SS concentration in the
tissue extracts was determined by a modified radioimmuno-
assay method [38], with a sensitivity limit of 10 pg/ml.
Incubation tubes prepared in duplicate contained 100-ml
samples of tissue extracts or standard solutions of 0 to 500
pg SS-14 diluted in phosphate buffer (0.05 M, pH 7.2,
containing 0.3% BSA, 0.01 M EDTA), 200ml of diluted
anti-SS serum, 100ml of freshly prepared [125I-Tyr11]SS
diluted in buffer to give 6000 cpm (equivalent to 5–10 pg),
in a final volume of 0.8 ml. All reagents as well as the assay
tubes were kept chilled on ice before their incubation for
48 h at 4°C. Bound hormone was separated from free
hormone by the addition of 1 ml of dextran-coated charcoal
(dextran T-70, 0.2% wt/vol, Pharmacia, Uppsala, Sweden;
charcoal: Norit A, 2% wt/vol Serva, Feinbiochemica, Hei-
delberg, Germany). Serial dilution curves for the samples
were parallel with the standard curve. The intraassay and
interassay variation coefficients were 6.0 and 8.8%, respec-
tively.
2.8. Pertussis toxin-catalyzed ADP-ribosylation
PTX-catalyzed ADP-ribosylation was performed as pre-
viously reported [4]. After PTX activation, membranes (0.8
mg of protein/ml) were incubated with PTX (16mg/ml) in
100 mM Tris-HCl buffer (pH 8.0) containing 10 mM thy-
midine, 1 mM ATP, 100mM GTP, 2.5 mM MgCl2, 1 mM
EDTA, and 2mM [32P]NAD1 (30 Ci/mmol) and an ATP-
regenerating system. After 30 min at 30°C, the reaction was
stopped by addition of 1 ml of ice-cold 100 mM Tris-HCl
buffer (pH 8.0) and the proteins were sedimented by cen-
trifugation for 10 min at 30 000g and solubilized with 0.1
ml 60 mM Tris-HCl buffer (pH 6.8) containing 10% glyc-
erol, 0.001% bromophenol blue, and 3% sodium dodecyl
sulfate (SDS) (SDS sample buffer). After heating for 30
minutes at 60°C, the suspension was centrifuged for 10 min
at 100 000g and aliquots of the supernatant were submitted
to SDS–polyacrylamide gel electrophoresis, using the pro-
cedure of Laemmli [28] as previously described [27]. The
gels were run, fixed, dried, and exposed to Dupont films
(cronex 4) for 1 to 7 days at280°C, using an intensifying
screen.
2.9. Statistical analysis
The computer program LIGAND [36] was used to ana-
lyze the binding data. Statistical comparisons of all the data
were performed with one-way analysis of variance and the
Student–Newman–Keuls test. Means among groups were
considered significantly different whenP was,0.05. Each
individual experiment was performed in duplicate.
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3. Results
The effect of SS-14 on FK-stimulated AC activity was
markedly decreased in pancreatic acinar membranes from
bombesin-treated rats compared with control animals after 7
and 14 days of bombesin administration (Table 1). It should
be noted that SS did not modify basal AC activity. To test
if the observed changes were related to modifications in the
expression of AC, we measured the response of AC to the
diterpene FK, which acts directly on the catalytic subunit of
AC. No significant differences were seen for either basal or
FK-stimulated AC activities between the control and bomb-
esin groups (Table 1).
The Gi proteins were evaluated by PTX labeling. Pan-
creatic acinar cell membranes from control and bombesin-
treated rats were incubated with PTX and [32P]NAD1 and
subsequently analyzed by SDS–polyacrylamide gel electro-
phoresis and autoradiography (data not shown). This tech-
nique labeled a 41-kDa band. The labeling intensity of this
band was similar in the membranes of all the groups studied.
Additional experiments were performed to explore the
effect of bombesin on the functionality of Gi proteins in rat
pancreatic acinar membranes. These included determination
of the ability of low Gpp(NH)p concentrations to inhibit
FK-stimulated AC activity. Use of this assay showed that
membranes derived from control rats yielded a characteris-
tic biphasic response curve (Fig. 1). Gpp(NH)p concentra-
tions between 0.01 and 1 nM decreased AC activity (P ,
0.05) because of Gi activation, whereas higher nucleotide
concentrations (10 nM) resulted in stimulation (P , 0.01) of
both AC and Gs activities. The inhibitory effect of Gpp
(NH)p on FK-stimulated AC activity, however, was mark-
edly decreased in pancreatic acinar membranes from bomb-
esin-treated rats (Fig. 1). These findings provide strong
evidence for a Gi functional abnormality in the bombesin-
treated rats.
Experiments were also performed to measure the inhibi-
tion of specific [125I-Tyr11]SS binding by the stable GTP
analog Gpp(NH)p (Fig. 2). These were performed to deter-
mine whether the reduced SS-mediated AC activity ob-
served in bombesin-treated rats could also be attributed to
alterations in the integrity of the SS receptor binding site–G
protein interaction. The IC50 of Gpp(NH)p is approximately
the same in the bombesin-treated and non–bombesin-
treated groups, suggesting no difference in potency.
Stoichiometric experiments with [125I-Tyr11]SS and in-
creasing concentrations of the unlabeled peptide (Fig. 3)
showed that in the animals treated with bombesin for 7 and
14 days, the maximal binding of [125I-Tyr11]SS to rat pan-
creatic acinar membranes was significantly lower than in
Fig. 1. Dose–effect curves for 59guanylylimidodiphosphate [Gpp(NH)p]
on forskolin (FK)-stimulated adenylyl cyclase (AC) activity in rat pancre-
atic acinar membranes from control (F) and rats treated with bombesin for
7 days (E) or 14 days (‚). The enzyme activity was measured in the
presence of 100 nM FK and the indicated concentrations of Gpp(NH)p.
Data are expressed as percentages of FK-stimulated activity (100%) in the
absence of Gpp(NH)p. Each point is the mean of three separate experi-
ments, each performed in duplicate.
Table 1
Effect of somatostatin (SS) (1029 M) and forskolin (FK) (1025 M) on adenylyl cyclase (AC) activity (pmol of cAMP/min/mg of protein) in pancreatic







Basal activity 14.76 1.3 15.16 1.3 13.96 1.3 15.36 2.1 14.36 1.1
11029 M of SS 12.66 0.8 14.36 1.5 13.16 1.5 13.56 0.9 12.96 1.2
1025 M FK 23.66 1.7 24.36 1.8 24.26 2.0 25.16 2.0 24.76 1.2
1025 M FK 1 1029 M 16.36 1.0 20.56 1.2 20.16 1.1 22.16 1.5 22.66 1.3
%SS inhibition of FK stimulation 30.96 1.7 15.66 1.4† 16.96 1.1† 11.96 0.9† 8.56 0.5†
14 days
Basal activity 15.16 0.8 16.16 1.7 14.26 1.6 16.26 1.9 15.26 1.5
11029 M of SS 13.06 1.0 14.26 1.1 12.96 1.3 14.56 1.4 13.76 1.1
1025 M FK 24.86 1.2 25.36 2.0 24.86 1.8 25.96 1.1 25.56 1.5
1025 M FK 1029 M SS 17.36 1.4 21.76 1.0 21.16 1.5 20.96 1.4 22.36 1.2
%SS inhibition of FK stimulation 30.36 1.7 14.26 1.1† 15.06 1.7† 19.36 1.3* 12.66 1.4†
Experiments were performed as described in Methods. Data are6 SEM values of five separate experiments, each performed in duplicate cAMP, adenosine
39, 59-cyclic nonophosphate.
Statistical comparison versus control: *P , 0.01; † P , 0.001.
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controls. Scatchard plots of the stoichiometric binding data
were linear and essentially parallel (Fig. 3). Interpretation
with the LIGAND computer program [36] resulted in the
best fit for a model with one SS receptor. Pancreatic acinar
membranes from bombesin-treated rats exhibited significant
decreases in the maximum SS binding capacity at the two time
periods studied (Table 2). The correspondingKd values, how-
ever, were unchanged after bombesin administration.
The percentage of labeled SS degraded by pancreatic
acinar membranes from each experimental group during the
binding experiments was similar in both treated and un-
treated animals (Table 3).
Because bombesin increases CCK and gastrin release,
these hormones could mediate the effects of bombesin on
the SS receptor–effector system. The pretreatment with the
gastrin/CCK receptor antagonist PG was used to evaluate
Fig. 2. Dose-effect curves for 59-guanylylimidodiphosphate [Gpp(NH)p] on
the specific binding of [125I-Tyr11]somatostatin ([125I-Tyr11]SS) (35 pM) to rat
pancreatic acinar membranes from control rats (F) and rats treated with
bombesin (7 days (E) and 14 days (‚)). The results express the values of a
pool of the control groups, because no differences among them were found.
Each point is the mean of six separate experiments, each performed in dupli-
cate. The calculated EC50 values were 0.43, 1.7, and 1mM, respectively.
Fig. 3. Left: Competitive inhibition of [125I-Tyr11]somatostatin ([125I-Tyr11]SS) (35 pM) binding to pancreatic acinar membranes by unlabeled somatostatin
(SS). The membranes (75mg of protein/ml) were incubated for 90 min at 20°C in the presence of 35 pM [125I-Tyr11]SS and increasing concentrations of
native peptide. Points correspond to values for control rats (F) and rats treated with bombesin [7 days (E) and 14 days (‚)]. Each point is the mean of five
separate experiments, each performed in duplicate. The results express the value of a pool of the control groups, because theBmax and theKd values of the
control groups were similar. Right: Scatchard analysis of the same data.
Table 2
Characteristics of [125I-Tyr11]somatostatin ([125I-Tyr11]SS) binding to
pancreatic acinar membranes from rats treated for 7 and 14 days with
saline, bombesin alone or combined with proglumide, and RC-3095




Bmax (fmol/mg of protein) 5236 37 5206 25
Kd (nM) 0.076 0.01 0.076 0.02
Bombesin
Bmax (fmol/mg of protein) 2816 71* 2886 54*
Kd (nM) 0.096 0.03 0.076 0.01
Proglumide1 bombesin
Bmax (fmol/mg of protein) 2856 27* 2796 32*
Kd (nM) 0.086 0.01 0.076 0.01
RC-30951 bombesin
Bmax (fmol/mg of protein) 1576 14
† 1536 21‡
Kd (nM) 0.096 0.01 0.076 0.01
RC-3095
Bmax (fmol/mg of protein) 2096 23
† 2056 31†
Kd (nM) 0.086 0.02 0.086 0.03
Binding parameters were calculated from Scatchard plots by linear regres-
sion to determine the total number of binding sites (Bmax, fentomoles of SS
bound per milligram of protein) and their equilibrium dissociation constant
(Kd, nM). Data are mean6 SEM values of the combined data from five rats
in each group. Determinations were made in duplicate for each experiment.
The results express the value of a pool of the control groups, because theBmax
andKd values of the control groups were not affected by the vehicle.
Statistical comparison versus controls: *P , 0.05; † P , 0.01;
‡ P , 0.001.
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whether the effects of bombesin on the pancreatic soma-
tostatinergic system involved the activation of gastrin/CCK
receptors. The combination of PG with bombesin failed to
affect the bombesin-induced changes in the SS receptor–
effector system (Tables 1–3). PG did not affect SS content
or the SS receptor–effector system (data not shown).
The bombesin antagonist RC-3095 had similar effects on
the number of SS receptors and on SS-mediated inhibition
of FK-stimulated AC activity as bombesin. Bombesin ad-
ministration in combination with its antagonist RC-3095
induced a greater SS-mediated inhibition of FK-stimulated
AC activity as well as a greater decrease in the binding
capacity of the SS receptors (Tables 1 and 2). Bombesin
administration did not affect amount of somatostatin-like-
immunoreactive content in the rat pancreas at the two time
periods studied (Table 4).
4. Discussion
In this study, we have shown that the ability of Gp-
p(NH)p to inhibit FK-stimulated AC activity was dimin-
ished in pancreatic acinar cell membranes from bombesin-
treated rats in addition to an already reported decrease in the
number of SS receptors and that both bombesin and its
antagonist RC-3095 have similar effects on the SS receptor–
effector system in rat pancreatic acinar membranes.
Recently, it has been reported that the adenosine 39,59-
cyclic monophosphate (cAMP) pathway is involved in the
inhibitory effect of SS on pancreatic exocrine secretion [48].
Therefore, in the present study we examined the effect of SS
on AC activity in pancreatic acinar cell membranes from
control and bombesin-treated rats. Our results confirm the
observations of other authors showing that SS inhibits FK-
stimulated AC activity but does not modify rat pancreatic
basal AC activity [17]. SS was a partial antagonist of FK-
stimulated AC activity in pancreatic acinar membranes, in
agreement with Heisler [17]. In this respect, it is well
established that the inhibition of FK-stimulated AC activity
by SS in pancreatic acinar cell membranes and other cell
types involves three protein components found in the
plasma membrane [12,42,43,47], ie, the SS receptor, the AC
catalytic unit, and the GTP binding protein Gi, which cou-
ples the SS receptor to the catalytic unit. Therefore, impair-
ment of any of these three components by bombesin could
attenuate the effect of SS. This study did not reveal any
defect in the AC catalytic unit because in membranes from
control or bombesin-treated animals, similar levels of ac-
tivity were noted after direct stimulation of this enzyme by
the diterpene FK.
Although bombesin did not vary the PTX-catalyzed
ADP-ribosylation of Gi proteins, nor the ability of Gp-
p(NH)p to inhibit binding of125I-Tyr11]-SS, the inhibitory
effect of Gpp(NH)p on FK-stimulated AC was markedly
decreased in pancreatic acinar membranes from bombesin-
treated rats. This, together with the decrease in the number
of SS receptors, would explain, at least in part, the attenu-
ated inhibition of FK-stimulated AC activity.
Although no changes in pancreatic SS content were de-
tected by radioimmunoassay, it has been shown that bomb-
esin stimulates pancreatic SS release [16]. In this case, an
increased SS release or turnover might then lead to downregu-
lation and sensitization of the SS receptor–effector system.
Because bombesin is a potent secretagogue of pancreatic
enzyme secretion [21], the decrease of the number of SS
receptors observed in bombesin-treated rats is consistent
with the view that SS may function as an inhibitor of
pancreatic exocrine secretion [3]. In this regard, other pan-
creatic secretagogues such as vasoactive intestinal peptide,
secretin, CCK, and carbachol have been shown to decrease
the maximum binding capacity of SS in pancreatic acinar
membranes [44].
The parameters of the SS receptors in the control rats
were similar to those previously reported by others [12,42,
47,48]. Although five SS receptor subtypes have been
cloned [22], the exocrine pancreas appears to express only
receptor subtype 2 (SSTR2) [5]. It is tempting to speculate
that the decrease in the SS receptor density in bombesin-
treated rats could result, at least in part, from downregula-
tion of the SSTR2 subtype.
The results of this study show that both bombesin and its
antagonist RC-3095 have similar effects on the SS receptor–
effector system. It is conceivable that molecules with dif-
ferent properties might produce similar effects through a
commonly activated system. It has been shown that chronic
administration of bombesin or GRP will result in a down-
Table 3
Degradation of the tracer [125I-Tyr11]somatostatin ([125I-Tyr11]SS) after
incubation with pancreatic acinar cell membranes from each
experimental group







Pancreatic somatostatin-like immunoreactivity (SSLI) levels in rats
treated for 7 or 14 days with saline, bombesin, or bombesin combined
with proglumide
Groups SSLI (ng of SS-14/mg of protein)
7 14
Saline 4.206 0.72 4.276 0.61
Bombesin 4.346 0.62 5.246 0.73
Proglumide1 bombesin 4.436 0.57 4.326 0.25
The SSLI levels are expressed as nanograms of SS per milligram of
protein. Data are mean6 SEM values of the combined data from five rats
in each group. Determinations were made in duplicate for each experiment.
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regulation of bombesin/GRP receptors similar to that pro-
duced by the antagonists of these peptides, such as RC-3095
[49]. This may explain why bombesin and RC-3095 have
similar effects. In this context, it is also well established that
treatment with bombesin and its antagonist RC-3095 de-
creases the binding capacity of epidermal growth factor
(EGF) receptors in pancreatic cancers [49]. The greatest
reduction in the concentration of EGF receptors and tumor
growth inhibition were observed after treatment with RC-
3095 plus GRP [49]. Recently, Vidal et al. [51] have shown
that EGF increases the SS receptor density as well as the
biological response to SS in pancreatic tumor AR42J cells.
Therefore, it is possible that the decrease in functional EGF
receptors induced by bombesin or its antagonist RC-3095
may be the common mechanism of action of both peptides
on the SS receptor–effector system.
The physiological role of the decrease in the SS recep-
tor–effector system induced by bombesin in the exocrine
pancreas cannot be stated at this time. However, bombesin-
like immunoreactivity was identified by immunocytochem-
istry within intrapancreatic nerves, both in the exocrine
portion of the gland and within the islets [26]. Specific
bombesin receptors have been functionally and structurally
identified in rat, mouse, guinea pig, and human pancreatic
acinar membranes [13,24,45]. Several findings support that
bombesin-like peptides are important in the mediation of the
pancreatic response to vagal stimulation in the anesthetized
rat model [37]. Thus, that bombesin, an activator of pan-
creatic enzyme secretion [21], inhibits the SS receptor–
effector system, which is considered to be an inhibitor of
this secretion [3], suggests that the regulation of SS binding
by bombesin could be physiologically important in permit-
ting the pancreas to secrete more enzymes after stimulation
of the organ.
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